[(2R,3S,4R,5R)-4-acetyloxy-3-benzoyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl benzoate | 99355-31-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: [(2R,3S,4R,5R)-4-acetyloxy-3-benzoyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl benzoate
• CAS: 99355-31-4
• 化学式: C₂₅H₂₂N₂O₉
• 分子量: 494.458
• InChiKey: FSLYMRHHQDGQAM-FVTFTPSCSA-N

物化性质

• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  138
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  [(2R,3S,4R,5R)-4-acetyloxy-3-benzoyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl benzoate 在 一水合肼 作用下， 以 吡啶 、 溶剂黄146 为溶剂， 反应 18.0h， 以80%的产率得到1-(3,5-di-O-benzoyl-β-D-xylofuranosyl)uracil
  参考文献：
  名称：

  Robins, Morris J.; Madej, Danuta; Hansske, Fritz, Canadian Journal of Chemistry, 1988, vol. 66, p. 1258 - 1262

  摘要：

  DOI：
• 作为产物：
  描述：

  Di-O-benzoyl-3,5 di-O-acetyl-1,2 α-D-xylofurannose 生成 [(2R,3S,4R,5R)-4-acetyloxy-3-benzoyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl benzoate
  参考文献：
  名称：

  ROBINS, MORRIS J.;MADEJ, DANUTA;HANSSKE, FRITZ;WILSON, JOHN S.;GOSSELIN, +, CAN. J. CHEM., 66,(1988) N 5, 1258-1262

  摘要：

  DOI：

文献信息

• Systematic synthesis and biological evaluation of .alpha.- and .beta.-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogs
  作者：Gilles Gosselin、Marie Christine Bergogne、Jean De Rudder、Erik De Clercq、Jean Louis Imbach

  DOI：10.1021/jm00152a007

  日期：1986.2

  anomers were obtained by a multistep synthesis with use of 2-amino- or 2-mercapto-alpha-D-xylofuran[1',2':4,5]-2-oxazoline as starting material. The xylofuranosyl nucleosides were tested for their activity against a variety of RNA and DNA viruses and for inhibition of cell growth and macromolecule synthesis. Three compounds, 9-(beta-D-xylofuranosyl)adenine, 9-(beta-D-xylofuranosyl)guanine, and 1-(

  天然存在的核苷的α-和β-D-木呋喃糖基类似物，以及其他D-木呋喃糖基衍生物，已成为其生物学（即抗病毒抗代谢和抑制细胞生长）特性的系统合成和研究对象。通过将嘌呤和嘧啶糖苷配基与过酰化的1-O-乙酰基-α-D-木呋喃糖基糖基化，然后除去保护基团来制备β端基异构体。通过使用2-氨基或2-巯基-α-D-木呋喃[1'，2'：4,5] -2-恶唑啉为起始原料的多步合成法获得α-端基异构体。测试了木呋喃糖基核苷对多种RNA和DNA病毒的活性以及对细胞生长和大分子合成的抑制作用。9-（β-D-木呋喃糖基）腺嘌呤三种化合物
• Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides
  申请人：——

  公开号：US20020035085A1

  公开（公告）日：2002-03-21

  A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

  一种治疗感染乙型肝炎的宿主的方法和组合物，包括给予所述2'-脱氧-β-L-赤霉糖核苷或其药用可接受的盐或前药的有效乙型肝炎治疗剂量。
• Synthesis of ?-D-xylofuranosyl- and 2,2?-anhydro-1-?-D-lyxofuranosylpyrimidine nucleosides
  作者：G. A. Tolstikov、A. G. Mustafin、R. R. Gataullin、L. V. Spirikhin、V. S. Sultanova、I. B. Abdrakhmanov

  DOI：10.1007/bf00704207

  日期：1993.6

  of silyl derivatives of pyrimidines with 1,2-di-O-acetyl-3,5-di-O-benzoyl-D-xylofuranose with subsequent deprotection of the sugar fragment. Refluxing 2-O-tosyl derivatives of nucleosides with NaI results in the formation of 2,2′-anhydro-compounds.

  摘要 通过嘧啶的甲硅烷基衍生物与 1,2-二-O-乙酰基-3,5-二-O-苯甲酰基-D-木呋喃糖缩合，随后对糖片段进行脱保护，获得 β-D-呋喃木糖基嘧啶。用 NaI 回流核苷的 2-O-甲苯磺酰基衍生物会导致形成 2,2'-脱水化合物。
• 2' or 3' -deoxy and 2' , 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents
  申请人：Gosselin Gilles

  公开号：US20050101776A1

  公开（公告）日：2005-05-12

  Method for the sterospecific preparation of 2′ or 3′ deoxy and 2′,3′-dideoxy-β-L-pentafuranonucleoside compounds. 2′ or 3′ deoxy and 2′,3′-dideoxy-β-L-pentofuranonucleoside compounds are also described. Finally, the invention concerns the use of these compounds, and particularly 2′,3′dideoxy-β-L-fluorocytidine, as drugs, and especially as anti-viral agents.

  一种立体选择性制备2′或3′去氧和2′,3′-二去氧-β-L-戊糖核苷化合物的方法。还描述了2′或3′去氧和2′,3′-二去氧-β-L-戊糖核苷化合物。最后，本发明涉及这些化合物的用途，特别是2′,3′-二去氧-β-L-氟胞嘧啶作为药物，特别是作为抗病毒剂。
• Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
  申请人：Standring David

  公开号：US20050080034A1

  公开（公告）日：2005-04-14

  It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

  已经发现β-L-2'-脱氧核苷可以对具有突变的耐药性乙型肝炎病毒产生活性。提供了一种治疗宿主中拉米夫定耐药性HBV（M552V）的方法，包括给予β-L-2'-脱氧核苷或其药学上可接受的盐、酯或前药。此外，提供了一种防止拉米夫定耐药性HBV（M552V）突变在未接触过的宿主中发生的方法，包括给予β-L-2'-脱氧核苷或其药学上可接受的盐、酯或前药。还提供了一种防止和/或抑制宿主中HBV双突变体（L528M / M552V）出现的方法，包括给予β-L-2'-脱氧核苷或其药学上可接受的盐、酯或前药。